Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/GSK3B_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/GSK3B_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/GSK3B_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/GSK3B_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/GSK3B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/GSK3B_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/GSK3B_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/GSK3B_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/GSK3B_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/GSK3B_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/GSK3B_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00019548 | Cervix | CC | positive regulation of cell-matrix adhesion | 15/2311 | 58/18723 | 3.75e-03 | 2.38e-02 | 15 |
GO:01060277 | Cervix | CC | neuron projection organization | 21/2311 | 93/18723 | 4.10e-03 | 2.54e-02 | 21 |
GO:00086259 | Cervix | CC | extrinsic apoptotic signaling pathway via death domain receptors | 19/2311 | 82/18723 | 4.57e-03 | 2.77e-02 | 19 |
GO:00190807 | Cervix | CC | viral gene expression | 21/2311 | 94/18723 | 4.68e-03 | 2.82e-02 | 21 |
GO:00182106 | Cervix | CC | peptidyl-threonine modification | 26/2311 | 125/18723 | 4.98e-03 | 2.97e-02 | 26 |
GO:00018374 | Cervix | CC | epithelial to mesenchymal transition | 31/2311 | 157/18723 | 5.25e-03 | 3.08e-02 | 31 |
GO:00309003 | Cervix | CC | forebrain development | 64/2311 | 379/18723 | 5.53e-03 | 3.19e-02 | 64 |
GO:00329847 | Cervix | CC | protein-containing complex disassembly | 41/2311 | 224/18723 | 6.13e-03 | 3.48e-02 | 41 |
GO:00353087 | Cervix | CC | negative regulation of protein dephosphorylation | 10/2311 | 34/18723 | 6.40e-03 | 3.58e-02 | 10 |
GO:00507733 | Cervix | CC | regulation of dendrite development | 22/2311 | 103/18723 | 6.75e-03 | 3.71e-02 | 22 |
GO:00485886 | Cervix | CC | developmental cell growth | 42/2311 | 234/18723 | 7.88e-03 | 4.15e-02 | 42 |
GO:19038286 | Cervix | CC | negative regulation of cellular protein localization | 24/2311 | 117/18723 | 8.10e-03 | 4.23e-02 | 24 |
GO:00215433 | Cervix | CC | pallium development | 32/2311 | 169/18723 | 8.73e-03 | 4.48e-02 | 32 |
GO:00068873 | Cervix | CC | exocytosis | 59/2311 | 352/18723 | 8.74e-03 | 4.48e-02 | 59 |
GO:0045665 | Cervix | CC | negative regulation of neuron differentiation | 16/2311 | 69/18723 | 8.75e-03 | 4.48e-02 | 16 |
GO:00487624 | Cervix | CC | mesenchymal cell differentiation | 42/2311 | 236/18723 | 9.12e-03 | 4.60e-02 | 42 |
GO:00320916 | Cervix | CC | negative regulation of protein binding | 20/2311 | 94/18723 | 9.92e-03 | 4.86e-02 | 20 |
GO:0006091 | Colorectum | AD | generation of precursor metabolites and energy | 209/3918 | 490/18723 | 3.17e-28 | 6.61e-25 | 209 |
GO:0015980 | Colorectum | AD | energy derivation by oxidation of organic compounds | 143/3918 | 318/18723 | 2.78e-22 | 2.49e-19 | 143 |
GO:0016032 | Colorectum | AD | viral process | 168/3918 | 415/18723 | 4.67e-20 | 3.66e-17 | 168 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GSK3B | SNV | Missense_Mutation | | c.46N>T | p.Pro16Ser | p.P16S | P49841 | protein_coding | tolerated_low_confidence(0.36) | benign(0.003) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GSK3B | SNV | Missense_Mutation | novel | c.857C>G | p.Pro286Arg | p.P286R | P49841 | protein_coding | deleterious(0.03) | benign(0.162) | TCGA-C8-A8HR-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
GSK3B | insertion | Nonsense_Mutation | novel | c.1146_1147insGAAACCGGGAGGCGGAGGTTGCATTGAGCCGAGATTGCGCC | p.Asn383GlufsTer9 | p.N383Efs*9 | P49841 | protein_coding | | | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
GSK3B | insertion | In_Frame_Ins | novel | c.44_45insATCACAAGGAGAACTCTGTTTTGA | p.Lys15_Pro16insSerGlnGlyGluLeuCysPheGlu | p.K15_P16insSQGELCFE | P49841 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GSK3B | deletion | Frame_Shift_Del | novel | c.850delN | p.Met284Ter | p.M284* | P49841 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
GSK3B | SNV | Missense_Mutation | novel | c.259G>A | p.Val87Ile | p.V87I | P49841 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GSK3B | SNV | Missense_Mutation | novel | c.683N>A | p.Ile228Asn | p.I228N | P49841 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GSK3B | SNV | Missense_Mutation | rs72548709 | c.995N>A | p.Arg332His | p.R332H | P49841 | protein_coding | tolerated(0.07) | benign(0.003) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
GSK3B | SNV | Missense_Mutation | | c.713N>C | p.Ile238Thr | p.I238T | P49841 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
GSK3B | SNV | Missense_Mutation | | c.901T>C | p.Trp301Arg | p.W301R | P49841 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | PMID26161698-Compound-18 | | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | Neu-120 | | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | SOTRASTAURIN | SOTRASTAURIN | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | CYC-116 | CYC-116 | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | tideglusib | TIDEGLUSIB | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | inhibitor | 404859135 | | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | ALSTERPAULLONE | ALSTERPAULLONE | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | inhibitor | CHEMBL1200826 | LITHIUM CARBONATE | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | AMO-02 | | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | BETULINIC ACID | BETULINIC ACID | 19716700 |